Astrazeneca

This study tests two experimental vaccines, AZD4117 and AZD5315, designed to protect against certain bird flu strains (H5N1 and H7N9). About 405 healthy adults will receive either a vaccine or a placebo to check for side effects and measure how well the vaccines trigger an immune…

This study tests a new treatment called AZD5851 for adults with advanced or recurrent liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are t…

This study offers continued treatment with durvalumab to cancer patients who have already completed a previous study and are still benefiting from the drug, as judged by their doctor. About 214 participants will be enrolled to monitor safety and side effects over time. The goal i…

This study tests whether a new combination of drugs (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone can keep early-stage lung cancer from returning after surgery. It includes 24 people with stage I adenocarcinoma non-small cell lung cancer who have signs of can…

This study tests two experimental treatments (Dato-DXd alone or with durvalumab) against standard options in people with triple-negative breast cancer who still have cancer cells in the breast or lymph nodes after surgery and chemotherapy. About 1,174 participants will be randoml…

This study tests whether the immunotherapy drug durvalumab works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, who have not h…

This study tests a combination of two drugs, capivasertib and fulvestrant, in Chinese patients with advanced or metastatic HR+/HER2- breast cancer that has returned or worsened after hormone therapy. About 258 participants will receive the treatment to see if it delays the need f…

This study tests whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) after standard chemoradiation can help keep limited-stage small cell lung cancer from growing or coming back. About 730 adults whose cancer did not worsen after initial treatment received …

This study tests an investigational drug called tozorakimab in adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year and have high levels of eosinophils (a type of white blood cell). Participants receive either tozorakimab or a pl…

This study tests an experimental drug called AZD6234 to see if it helps people with type 2 diabetes and overweight or obesity lose more weight when added to their current stable GLP-1 medication. About 69 adults will receive either AZD6234 or a placebo for 26 weeks. The main goal…

This study tests whether adding the experimental drug monalizumab to the standard drug cetuximab helps people with advanced head and neck cancer live longer. The trial includes 370 adults whose cancer returned or spread after prior treatments, including immunotherapy. Participant…

This study tests whether taking osimertinib for 5 years after surgery can stop EGFR-mutant lung cancer from coming back. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug daily. The main goal is to see how long the…

This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has gotten worse after initial osimertinib treatment. About 98 participants w…

This study follows 155 people with severe asthma who are starting a new medicine called tezepelumab. Researchers want to see how well it controls asthma symptoms and improves quality of life over two years in real-world clinics across Greece. The goal is to understand if this tre…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer. About 1,063 participants will receive either the drug combo or standard care. The goal is to see i…

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This study tests whether adding the immunotherapy drug durvalumab (alone or with another drug, tremelimumab) to standard chemotherapy helps people with advanced bladder cancer live longer. About 1,200 participants who have not had prior chemotherapy will receive either the drug c…

This study tests a drug called anifrolumab for people with lupus-related skin rashes that haven't improved with standard treatments. About 306 adults will receive either the drug or a placebo to see if it reduces rash severity by 70%. The goal is to control the disease, not cure …

This study tests two new drug combinations for people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. About 712 participants will receive either a combination of three drugs (durvalumab, tremelimumab, and enfortumab vedotin) or two dr…

This study looks at how safe and effective the drug selumetinib is for children aged 3 to 16 with a rare genetic condition (NF1) that causes painful, non-cancerous tumors. About 80-100 kids in China will be followed for 2 years while taking the medication. The goal is to see if t…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people with HER2-positive breast cancer that has spread. The goal is to find safe doses and see how well the combinations shrink tumors. About 245 adults with advanced or metasta…

This study tests whether the drug benralizumab can help people with severe eosinophilic asthma safely reduce their daily controller medications. About 504 Chinese patients aged 12 to 75 will try to step down their usual asthma treatments while staying on benralizumab. The goal is…

This study tests whether adding the drug durvalumab to standard chemoradiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 640 adults will receive either durvalumab or a placebo alongside their radiation and chemotherapy. The goal is to s…

This study tests whether a combination of two drugs (zibotentan and dapagliflozin) works better than dapagliflozin alone at slowing kidney function loss in people with chronic kidney disease and high proteinuria. About 1835 adults with moderate to severe kidney disease are taking…

This study tests a combination of two drugs, ceralasertib and durvalumab, in adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors and …

This study follows 1620 lupus patients who are not responding well to current treatments to see how safe and effective Saphnelo (anifrolumab) is over the long term. Researchers will monitor for side effects like infections and allergic reactions. The goal is to gather real-world …

This study tests a new daily pill, AZD0780, to lower LDL (bad) cholesterol in adults who already have heart disease or are at high risk for it. About 3,100 participants will receive either the study drug or a placebo for 52 weeks, and neither they nor their doctors will know whic…

This study tests a combination of two drugs, capivasertib and fulvestrant, in people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see how well the combo works in real-world…

This study tests whether adding the drug durvalumab to precise, high-dose radiation (SBRT) helps keep early-stage lung cancer from coming back in patients who cannot have surgery. About 724 adults with stage I/II non-small cell lung cancer will receive either durvalumab or a plac…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) with or without a targeted therapy (lenvatinib) to a standard procedure called TACE can help people with liver cancer that cannot be surgically removed. About 760 participants will be randomly a…

This study tests a new drug (AZD0171) combined with two other treatments (durvalumab and chemotherapy) in 126 people with advanced pancreatic cancer. The goal is to see if the combination is safe and helps control the cancer longer. This is not a cure, but aims to slow the diseas…

This study tests a drug called volrustomig in 30 women with advanced cervical cancer (stage IIIA to IVA) who have finished standard chemoradiation without their cancer getting worse. The goal is to see if volrustomig can help keep the cancer from returning or spreading. Participa…

This study tests a new injectable drug, anifrolumab, for adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding anifrolumab can better control lupus activity and reduce flare-ups. About 367 participan…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutated non-small cell lung cancer. About 532 adults with stage IIIB, IIIC, or IV lung cancer that cannot be surgically removed are being observ…

This study tests a daily pill called AZD9291 (osimertinib) against a placebo in people with a specific type of lung cancer (EGFR mutation-positive) that has been removed by surgery. The goal is to see if the drug can delay or prevent the cancer from returning. About 682 adults wi…

This study looks at how long people with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib when it's used in regular medical practice in Italy. Researchers will track 151 patients who started the drug between 2021 and 2022, noting why some stop treatment. The goal…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people whose breast cancer has spread and has low levels of a protein called HER2. The main goals are to see if the combinations are safe and to find the best doses. About 138 ad…

This early-stage study tests a new drug combination (ceralasertib plus durvalumab) in Chinese patients with advanced solid tumours that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the drugs move through the …

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced lung cancer who haven't had treatment before. About 950 adults with a specific type of non-small cell lung cancer took…

This study tests an investigational drug called tozorakimab in about 1,450 adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year. Participants must already be on standard inhaled therapy. The main goal is to see if the drug can re…

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It involved 162 adults whose cancer had responded to platinum-based treatment before.…

This study tested whether the drug durvalumab can help people with stage III lung cancer that cannot be surgically removed. After completing chemotherapy and radiation, 407 participants received either durvalumab or a placebo every few weeks. The goal was to see if durvalumab cou…

This early-phase study tests a new drug called AZD9833, alone or with other treatments, in 396 women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. Researchers will also measure how well the…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, in children aged up to 17 with advanced solid tumors or certain blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs can s…

This study tests whether adding baxdrostat to the standard drug dapagliflozin can better slow kidney disease in adults with chronic kidney disease and high blood pressure. About 2,500 participants will receive either the combination or dapagliflozin alone for 24 months. The goal …

This study tests whether adding the drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from returning after surgery. About 757 adults who had their tumor completely removed will receive either rilvegostomig plus chemo or a placebo plus chemo. The go…

This study tests whether adding the drug AZD2811 to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer under control after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy. The goal is …

This study tests a new drug (AZD5305) combined with standard hormone therapies in people with metastatic prostate cancer that has spread. The goal is to check safety, how the drug moves through the body, and early signs of effectiveness. About 174 adults whose cancer has spread a…

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink t…

This study tests whether taking olaparib daily after initial chemotherapy can delay the return of advanced ovarian cancer in women with BRCA gene mutations. About 450 women whose cancer responded to platinum-based chemo will receive either olaparib or a placebo. The goal is to se…

This study tests a new combination of two drugs (ceralasertib and durvalumab) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has worsened after previous treatments. About 594 participants will be randomly assigned to one of the t…

This study tests an investigational drug called tezepelumab in 368 people aged 12 to 80 with eosinophilic esophagitis, a condition that makes swallowing difficult due to allergic inflammation in the esophagus. Participants receive either the drug or a placebo as a shot under the …

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests a new treatment for people with triple-negative or hormone receptor-low breast cancer that hasn't been treated yet. About 1,900 adults will get either the experimental drugs (datopotamab deruxtecan plus durvalumab) or the current standard treatment (pembrolizumab…

This study is for people with advanced hormone-positive, HER2-negative breast cancer that has a specific gene change (ESR1 mutation). Participants currently stable on standard therapy will either switch to a new oral drug (AZD9833) plus a CDK4/6 inhibitor or stay on their current…

This study offers continued treatment with the drug osimertinib to cancer patients who were already benefiting from it in a previous clinical trial. The goal is to keep providing the drug while monitoring for serious side effects. About 37 participants are enrolled, and the study…

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without carboplatin, in 155 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the combination is safe and shrinks tumors. This is an early-…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (e.g., ovarian, breast, prostate, lung cancer). The goal is to see if the drug is safe and can shrink tumors when given alone or with other anti-cancer medicines. About 70…

This study tests if tezepelumab, a monthly injection, can help people with severe asthma safely reduce their daily maintenance inhaler (SYMBICORT) while still keeping their asthma under control. About 326 adolescents and adults will be followed for up to 72 weeks. The goal is to …

This study tests a combination of two drugs, MEDI4736 (an immunotherapy) and olaparib (a targeted therapy), in people with advanced solid tumors like ovarian, breast, lung, and stomach cancers. The goal is to see if the combo can shrink or stabilize tumors. About 264 participants…

This study tests a combination of three drugs (durvalumab, tremelimumab, and lenvatinib) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 114 participants will receive the drugs to see if they can slow cancer growth and improve…

This phase 3 study tests whether adding capivasertib to fulvestrant can slow the growth of advanced or metastatic HR+/HER2- breast cancer in people whose cancer worsened after aromatase inhibitor treatment. About 818 adults are enrolled. The main goal is to see how long the cance…

This study tests a new drug called AZD6244 given with standard chemotherapy for people with advanced solid tumors (like breast, colon, lung, melanoma, or kidney cancer) that have no curative options. The main goal is to see if the combination is safe and tolerable, and to find th…

This study tests whether the drug osimertinib, taken as a pill after surgery, can help prevent lung cancer from coming back in people with a specific rare gene change (uncommon EGFR mutation). About 51 adults with stage IB-IIIB non-small cell lung cancer will take the drug daily …

This study looks at how well ravulizumab works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice in Poland. Researchers will track 64 adults already receiving the drug, measuring blood markers and how many blood transfusions they need. The goa…

This study tests whether a new drug called volrustomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. About 1,200 participants whose tumors have low leve…

This study tracks the safety of selumetinib, a drug for children with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors. About 124 children aged 3 to 18 across Europe and Israel will be monitored for side effects like heart changes, bone growth issues, musc…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with advanced solid tumors that have a specific HER2 gene mutation. The goal is to see if the drug can shrink tumors in patients who have already tried other treatments. The study includes 102 adults with var…

This study follows 192 adults in Spain with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug after 24 months, especially those new to treatment or switching due to side effects from …

This study tests whether adding olaparib to standard treatment (abiraterone) can help men with a certain type of advanced prostate cancer live longer without their cancer getting worse. About 895 men who have not had chemotherapy or newer hormone drugs for this stage of cancer ar…

This study tests whether combining two experimental weekly injections (AZD9550 and AZD6234) helps people with obesity or overweight who also have weight-related health problems lose more weight than placebo or either drug alone. About 377 adults aged 18-75 with a BMI of 27 or hig…

This study is for people with muscle-invasive bladder cancer that has gotten worse after previous treatments. It tests several different drug combinations, chosen based on the specific genetic markers in each person's tumor. The main goal is to see if these combinations are safe …

This study tests whether adding the drug capivasertib to standard hormone therapy (abiraterone plus ADT) can slow cancer growth better than standard therapy alone in men with a specific type of advanced prostate cancer that has spread and lacks a protein called PTEN. About 1,000 …

This study tested a new oral drug, AZD9833, against a standard injected drug (fulvestrant) in 240 women with advanced ER-positive, HER2-negative breast cancer. The goal was to see which treatment better delayed cancer growth. Results from one dose group (300mg) are less reliable …

This study tests whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 adults with liver cancer that cannot be surgically removed will participate. The goal is to…

This study tests a new drug called savolitinib against a standard treatment (sunitinib) for people with a rare, advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib works better at slowing cancer growth and has fewer side effe…

This study follows 152 adults with COPD who start taking a three-in-one inhaler (budesonide/glycopyrronium/formoterol, or BGF) as part of their routine care. Researchers want to see how the treatment affects symptoms, quality of life, and the number of flare-ups over six months. …

This study tests whether a targeted drug called acalabrutinib works better than a standard combination of chemotherapy (chlorambucil) and an antibody (rituximab) for people with untreated chronic lymphocytic leukemia (CLL). About 155 adults aged 65 or older (or younger with certa…

This study tests whether adding olaparib to standard abiraterone therapy can delay cancer growth in men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet had chemotherapy or newer hormone drugs. About 110 participants will receive either the combinatio…

This study tests whether a special care program for hospitals can help people with COPD recover better after a serious flare-up. About 1,368 patients from 36 hospitals will take part. The program focuses on making sure patients get the right follow-up care and medications to prev…

This study tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or chemoradiation can help people with stage IIB-IIIB non-small cell lung cancer. About 142 participants will receive the drug combination first, then either have sur…

This study tests whether combining two immunotherapy drugs, durvalumab and oleclumab, can help people with advanced lung cancer that hasn't spread after initial chemoradiation. About 30 adults with stage III non-small cell lung cancer will receive the drug combo. The main goal is…

This study tests a combination of two drugs—BCG (a standard immunotherapy for bladder cancer) and durvalumab (an immune-boosting drug)—in adults with high-risk non-muscle-invasive bladder cancer who have not received BCG before. The goal is to see if the combination is safe and e…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and rituximab) in people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood and keep it under control. Participants who respond well may s…

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has specific gene mutations (S…

This study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors. The goal is to see if the drug can shrink these tumors and reduce pain. About 145 participants will receive either selumetinib or a placebo to measu…

This study looks at whether benralizumab can help repair lung structure and improve breathing in people with severe asthma caused by high levels of certain white blood cells (eosinophils). About 75 adults aged 18-70 with persistent symptoms despite standard inhaler therapy will r…

This study tests a new drug called trastuzumab deruxtecan (T-DXd), given alone or with another drug (pertuzumab), for people with HER2-positive breast cancer that has spread. It compares these options to the current standard treatment. About 1,157 adults with advanced or metastat…

This study tests whether adding savolitinib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, MET-positive) whose cancer has worsened on osimertinib alone. About 345 adults will be randomly assigned to receive either the drug combination o…

This study tests whether adding selumetinib to standard chemotherapy (docetaxel) helps people with advanced KRAS-mutant lung cancer live longer without their disease getting worse. About 510 adults who have already tried one treatment are taking part. The goal is to see if the co…

This study tests the drug dapagliflozin in 731 Chinese adults with chronic kidney disease to see if it can slow kidney function decline and reduce complications. Participants take the drug alongside their current treatments. The goal is to gather safety and effectiveness data for…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with other cancer drugs, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug shrinks tumors or slows their growth. About 127 adults with tumors that cannot be …

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a change in the MET gene. About 47 adults in China with this specific type of lung cancer will receive the treatment. The main goal is to se…

This study tests an investigational drug called eplontersen in 64 Chinese adults with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. The goal is to see if eplontersen can safely lower those protein levels compared to a placebo ove…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance therapy with or without olaparib, can help people with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 …

This study tests a new drug, trastuzumab deruxtecan (T-DXd), against standard chemotherapy in 866 people with a common type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The goal is to see if T-DXd can delay cancer…

This early-stage study tests a new drug called AZD1705 in about 98 adults with high cholesterol. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as a shot, and researchers monitor side effects and chol…

This study tests whether a combination of acalabrutinib and venetoclax can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as the standard venetoclax plus obinutuzumab regimen. About 607 adults who have not yet been treated for their disease will receiv…

This study tests a new drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has spread or cannot be removed. Participants must have a specific protein (CLDN18.2) on their cancer cells and have already tried at least one prior treatment. …

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer with a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will rece…

This study tests whether anifrolumab, an injected drug, can help people with systemic sclerosis (scleroderma) — a disease that causes skin thickening and can damage organs like the lungs. About 314 adults aged 18 to 70 with early-stage disease will receive either the drug or a pl…

This study tests a new drug, Dato-DXd, against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to one of the two treatments. The goal is to see if Dato-DXd can slow can…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in about 500 people with advanced HER2-positive breast cancer that has spread or cannot be removed. Some participants have brain metastases, others do not. The goal is to see how well the drug shrinks tumors and how lo…

This study tests whether the drug durvalumab, alone or with bevacizumab, can keep liver cancer from returning after surgery or ablation. About 900 people who had their liver cancer removed but are at high risk of recurrence will receive either the study drugs or a placebo. The go…

This study tests whether a daily pill called osimertinib can stop early-stage lung cancer from coming back after surgery. About 390 people with a specific gene mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either osimertinib or a placebo for up to 3 ye…

This study tests two experimental drug combinations (durvalumab plus oleclumab or monalizumab) in adults with stage III lung cancer that cannot be removed by surgery. Participants have already completed chemotherapy and radiation and their cancer has not grown. The goal is to see…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations to see which ones might work better based on the specific features of each person's t…

This study follows 416 adults with severe asthma that is not controlled by existing treatments. Participants receive Tezspire injections over a long period to check for side effects and how well the drug works. The goal is to confirm the drug's safety and effectiveness in real-wo…

This study tests whether adding new cancer drugs to the immunotherapy durvalumab, with or without chemotherapy, can safely control advanced lung cancer. It involves 175 adults with stage IV non-small cell lung cancer who have not had prior treatment for their metastatic disease. …

This study tests an experimental drug called AZD0780 in adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if the drug safely lowers 'bad' LDL cholesterol more than a placebo. About 473 participants w…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with several types of advanced cancers that have a specific protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cer…

This early-phase study tests a new drug called ceralasertib, given by mouth, combined with standard chemotherapy or other cancer drugs. The goal is to find safe doses and check for side effects in 354 adults with advanced solid tumors that no longer respond to standard treatments…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps people with a specific genetic type of stage III lung cancer that cannot be removed by surgery. About 76 adults with EGFR-mutated non-small cell lung cancer will receive o…

This study tested whether adding the immunotherapy drugs durvalumab and tremelimumab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. About 1,200 adults whose cancer had spread and who had not received prior treatment took part. The goal…

This study tests a new drug, benralizumab, against an existing one, mepolizumab, for people with a rare disease called EGPA that causes inflammation in blood vessels. About 140 adults with active disease despite standard care will receive either drug for a year, with the goal of …

This study looks at how well tezepelumab works for people aged 12 and older with severe asthma in Russia. It tracks symptom control over 52 weeks using patient questionnaires. The goal is to understand the real-world benefits of this treatment.

This study tests a drug called trastuzumab deruxtecan (T-DXd) against standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change (HER2 mutation). About 454 adults who have not had prior treatment for their advanced cancer will be ra…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells. About 119 participants will receive the drug ever…

This phase 3 study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) works better than osimertinib alone for people with advanced EGFR-mutant non-small cell lung cancer. About 587 participants are randomly assigned to receive either the combination or …

This study tests whether combining two drugs, durvalumab and olaparib, can help people with advanced bladder cancer that has spread and cannot be removed by surgery. Participants are those who cannot receive standard platinum-based chemotherapy. The goal is to see if the combinat…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 366 women with a specific type of ovarian cancer that does not have a BRCA gene mutation will receive either olaparib or a placebo daily. The goal i…

This study tests whether a new drug called volrustomig, alone or combined with casdatifan, works better than the current standard treatment (nivolumab plus ipilimumab) for people with advanced clear cell kidney cancer. About 1,116 adults with advanced or metastatic kidney cancer …

This study is observing about 90 adults with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care in Russia. Researchers are collecting data from medical records to see how long patients live without their cancer getting worse and …

This study watches 551 lupus patients who are starting anifrolumab for the first time as part of their normal care. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to understand the real-world…

This study offers continued access to the drug olaparib for people with ovarian or breast cancer who were already taking it in a previous study and are still benefiting. The goal is to keep providing the treatment while monitoring for serious side effects. About 185 participants …

This study tested two immunotherapy drugs (durvalumab alone or combined with tremelimumab) against standard chemotherapy in over 1,100 people with stage IV bladder cancer that could not be removed by surgery. The goal was to see if these treatments helped people live longer. The …

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple-negative breast cancer in people who haven't had prior treatment for advanced disease. About 243 women with advanced…

This study tests whether combining the targeted drug AZD9291 with either AZD6094 or selumetinib is safe and can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after prior targeted therapy. About 344 adults whose cancer has a specifi…

This study tests whether adding the drug durvalumab to standard chemotherapy (FLOT) before and after surgery helps people with stomach or gastroesophageal junction cancer live longer without the cancer coming back. About 957 participants will receive either durvalumab or a placeb…

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers. The drug works by blocking a protein that helps cancer cells grow. The main goal is to check safety and side effects, and to see how well the drug works. About 35 people will take …

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This early-stage study tests a new drug called AZD0780 in 40 healthy adults with high LDL (bad) cholesterol. The goal is to see if it safely lowers cholesterol levels compared to a placebo. Participants take the drug or placebo by mouth and are monitored for side effects and how …

This study tests whether adding the drug durvalumab to standard chemotherapy and radiation helps people with stage III lung cancer that cannot be removed by surgery. About 328 participants received either durvalumab or a placebo alongside their usual treatment. The main goal is t…

This study tests whether adding a drug called savolitinib to the standard treatment osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified). About 30 adults whose cancer got worse on osi…

This study tests whether a two-drug immunotherapy combination (durvalumab and bevacizumab) given after a precise internal radiation treatment (TARE) can help control liver cancer that cannot be removed by surgery. About 58 adults with this type of liver cancer will receive the ra…

This study was designed to test new cancer drugs, chosen based on specific biomarkers, for people with advanced or recurrent ovarian cancer. The goal was to see if these drugs were safe and effective. However, the trial was withdrawn before any participants were enrolled.

This phase 3 study compares a new drug called Dato-DXd with standard chemotherapy in people whose HR-positive, HER2-negative breast cancer has spread and is no longer responding to hormone therapy. About 732 participants who have already had 1-2 prior chemotherapies will be rando…

This early-stage study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The main goals are to check the drug's safety and how the body processes it, while also measuring …

This study tests a new oral drug (camizestrant) plus palbociclib against a standard treatment (anastrozole plus palbociclib) for people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be fo…

This study looks at whether two different doses of Nexium can keep erosive esophagitis (a condition where the esophagus is damaged by stomach acid) from coming back in children aged 1 to 11. About 53 kids who have already healed from the condition will take Nexium for 16 weeks. D…

This study looks at whether changing the rescue inhaler from albuterol alone to albuterol plus budesonide can lower the number of severe asthma attacks. About 1,500 adults with asthma who have had at least one severe attack in the past year will switch to the new inhaler. Researc…

This study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer who had not received prior treatment. Over 1,100 participants worldwide were enrolled. The main goals were t…

This study compares the drug olaparib to standard treatments (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone therapy and who have BRCA1/2 gene mutations. The goal is to see if olaparib can delay cancer growth bette…

This study tests a new granule (sprinkle) form of the drug selumetinib in children aged 1 to 6 years who have neurofibromatosis type 1 (NF1) and painful, inoperable tumors called plexiform neurofibromas. The goal is to find the right dose, check safety, and see if the medicine ca…

This study checks if a new version of a common asthma inhaler works just as well as the current one. About 422 adults with asthma will use both inhalers and a placebo to compare lung function. The goal is to make sure the new propellant is safe and effective.

This early-phase study tested a new oral drug called AZD6244 in 58 adults with advanced solid tumors that had stopped responding to standard therapies. The main goal was to check the drug's safety and how the body processes it. Researchers monitored side effects, vital signs, and…

This study follows about 254 adults with extensive-stage small cell lung cancer who are getting durvalumab (an immunotherapy) plus standard chemotherapy as their first treatment. Researchers want to see how long patients stay on treatment and how long they live in real-world sett…

This study tests whether the drug benralizumab can prevent or delay flare-ups in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause damage to organs. About 134 participants aged 12 and older will receive ei…

This phase 3 study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps people with high-risk non-muscle-invasive bladder cancer stay cancer-free longer. About 1,018 adults who have not had BCG before will be randomly assigned to receive either t…

This study tests a drug called durvalumab combined with standard chemotherapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that cannot be removed by surgery. The goal is to see if the combination is safe and helps patients live longer or shrink …

This study tests whether anifrolumab can help adults with active lupus nephritis, a serious kidney condition caused by lupus. About 359 participants will receive either the drug or a placebo to see if it improves kidney function and reduces the need for steroids. The goal is to c…

This study tests a new combination of drugs (datopotamab deruxtecan, durvalumab, and carboplatin) against the current standard treatment for advanced non-small cell lung cancer (NSCLC) that has not spread to the brain or bones. About 1,350 adults with stage IIIB, IIIC, or IV NSCL…

This study tested adding the immunotherapy drug durvalumab to standard chemotherapy for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. About 810 participants received either durvalumab plus chemo or a placebo plus chemo. The goal was to se…

This study looks at whether taking the drug selumetinib with a low-fat meal reduces stomach side effects in teenagers with neurofibromatosis type 1 (NF1) who have tumors that cannot be removed by surgery. About 24 teens will take the drug under both fed and fasted conditions to c…

This study tests a drug called acalabrutinib in Chinese adults whose mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers have come back or stopped responding to treatment. The goal is to see if the drug is safe and helps shrink tumors. About 105 participan…

This study tests whether adding olaparib to durvalumab as maintenance therapy can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy plus durvalumab will receive either th…

This study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people in Spain with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see if the treatment is safe and helps control the can…

This study tests a drug called tozorakimab in people with COPD who have had flare-ups in the past. The goal is to see if it can reduce the number of severe breathing attacks over time. About 1,700 adults who completed earlier studies will take either the drug or a placebo for lon…

This study tests a drug called trastuzumab deruxtecan (T-DXd), given alone or with other treatments before surgery, in people with high-risk HER2-positive early breast cancer. The goal is to see if it can eliminate all signs of cancer by the time of surgery. About 927 adults with…

This study tests whether taking osimertinib daily after standard chemoradiation can delay cancer growth in people with stage III EGFR-mutated non-small cell lung cancer that hasn't spread. About 216 participants worldwide will receive either osimertinib or a placebo. The goal is …

This study tests an experimental drug called AZD2936 in people with advanced or metastatic non-small cell lung cancer (NSCLC). The drug is designed to help the immune system fight cancer by blocking two targets (TIGIT and PD-1). The main goals are to check safety and see if the d…

This study tested adding the immunotherapy drug durvalumab (with or without another drug, tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either the drug combo or…

This large Phase 3 study tests whether adding the drug capivasertib to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants with inoperable or metastatic disease are randomly assigned to receive either the…

This study tested whether adding another targeted drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial included 273 adults whose tumors had specific gene changes affec…

This study tests an experimental drug called AZD9829 in 56 adults with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and to check for side effects. The drug is given through a vein, either alon…

This study tests a new drug called AZD7798 in 120 adults with moderate to severe Crohn's disease. Participants receive either the drug or a placebo to see if it reduces symptoms and improves gut healing. The goal is to find a better treatment option for people who haven't respond…

This large Phase 3 trial tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than the standard treatment (sorafenib) for advanced liver cancer that cannot be surgically removed. The study involved 1,324 adults with advanced liver cancer who had not re…

This study is testing whether adding a second drug called savolitinib to an existing drug (osimertinib) can help control advanced non-small cell lung cancer that has started growing again after initial treatment. It will involve about 367 adults whose cancer has specific genetic …

This study tests an artificial intelligence (AI) tool that analyzes chest X-rays to give a lung nodule malignancy score, predicting the risk of lung cancer. Researchers will compare the AI's score with CT scan results from 712 adults aged 35 and older who have a lung nodule. The …

This study tracks over 800 heart failure patients in Germany who are starting dapagliflozin, a recently approved drug. Researchers will observe how long patients stay on the medication, any side effects, and changes in symptoms and quality of life. The goal is to understand how t…

This early-stage study tests different versions of an experimental drug called AZD6234 in 21 healthy adults with overweight or obesity. The goal is to see which formulation gets into the blood best and causes the fewest side effects. Participants receive a single injection and ar…

This study looks at whether educating doctors in smaller city and county hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted therap…

This study is building a registry of 5000 adults with chronic kidney disease (CKD) to collect information on their health, treatments, and outcomes. The goal is to understand how CKD progresses, identify risk factors, and see how well current care matches guidelines. Participants…

This study watches 315 people with severe asthma who are starting a drug called tezepelumab in Italy. It aims to learn about their health history and how well the drug controls asthma attacks over two years. No new treatment is given—just observation of real-world results.

This study compares how well the body absorbs two different pill forms of the experimental drug AZD2281 in people with advanced solid tumors that no longer respond to standard treatments. About 197 participants will receive both forms in a random order to measure drug levels and …

This study looks at how the drug durvalumab works in everyday medical practice for people with a certain type of advanced lung cancer (NSCLC) that cannot be removed by surgery. Researchers will track about 250 patients in Russia to see how safe the drug is and how long people sta…

This study looks at how chronic lymphocytic leukemia (CLL) patients in Romania are doing while taking the drug acalabrutinib in everyday medical practice, not in a strict research setting. Researchers will collect information from 250 patients' medical records over 3 years to see…

This study looks at how a new drug called AZD5004 changes the way the body processes two diabetes drugs, mitiglinide and pioglitazone. It involves 32 healthy adults and aims to measure drug levels and safety. The results will help guide proper dosing in future studies.

This early-phase study tests the safety and how the body processes a single dose of the experimental drug AZD0292 in 18 healthy Japanese adults. Participants receive either the drug or a placebo by IV infusion. The main goal is to check for side effects and measure drug levels in…

This study looks at how an experimental drug called AZD6793 changes the way metformin works in people with type 2 diabetes. About 28 adults on a stable dose of metformin will take AZD6793 or a placebo for a short time, and researchers will measure blood sugar levels. The goal is …

This study observes 100 adults in Russia who have a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD). Researchers will collect information from medical records and follow-ups to see what treatments doctors use and how patients fare over time. No exper…

This early-phase study looks at how a common drug called rifampicin changes the way the body handles the experimental cancer drug cediranib. It involves 64 adults with advanced solid tumors that no longer respond to standard treatments. The goal is to understand the drug interact…

This study watches how Chinese asthma patients use biologic medicines and how well they work. About 202 people will be followed for a year while getting their usual care. The goal is to learn about treatment patterns, not to test a new drug.

This study will observe how doctors in Russia treat chronic lymphocytic leukemia (CLL) in everyday practice, without giving any experimental treatments. About 6,000 adults with CLL will have their medical records reviewed for up to 2 years to see which therapies are used and how …

This study looks at over 1,500 people in Russia with moderate-to-severe COPD who have frequent lung attacks (exacerbations). Researchers will collect information on their health habits, other illnesses, and current treatments to better understand this group. The goal is to descri…

This study watches how Chinese patients with a rare kidney disease called aHUS are treated in real-world clinics. Researchers will follow 367 children and adults for up to 12 months to see what treatments they receive and how their health changes. The goal is to learn more about …

This study tracks how the experimental drug AZD4144 moves through the body in 8 healthy men aged 30–65. Participants receive a single dose either by mouth or injection, with a tiny radioactive tag to follow the drug's breakdown and elimination. The goal is to understand absorptio…

This study observes 274 adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It looks at how doctors use the drug osimertinib as the first treatment and how patients do over 36 months, including survival and quality of life. The goal…

This study looks at 625 people in Russia with high-risk early breast cancer to find out how common BRCA1/2 gene mutations are and what treatments they receive. Participants are already diagnosed and treated, and researchers will collect data from medical records and genetic tests…

This study was designed to help doctors better manage serious bleeding in patients taking blood thinners. It planned to include 168 adults in Brazil who were on long-term blood thinners and had a major bleed. The study was withdrawn before enrolling anyone, so no results are avai…

This study was designed to track how often people in Egypt have severe COPD flare-ups and how those flare-ups affect their health and healthcare use. It planned to look back at medical records of patients over 40 with COPD for at least three years. However, the study was withdraw…

This study is not testing a new treatment. Instead, it observes how lupus (SLE) is diagnosed, how it changes over time, and what treatments doctors use in routine practice in Kazakhstan. About 509 adults with lupus will be followed to collect information on disease activity, orga…

This study tests whether a single tablet containing both laroprovstat and rosuvastatin works as well as taking the two drugs separately. It involves 44 healthy adults aged 18 to 55 who will receive different doses in a crossover design. The goal is to measure how much of each dru…

This study looks at how long people with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib and why they might stop. It follows 350 patients from 70 French hospitals for up to 3 years, using medical records. The goal is to see how the drug performs in real life, no…

This study is observing about 1,200 people with myasthenia gravis (MG) in China to understand how doctors currently treat the disease and how patients feel over time. Participants will have check-ups every 6 months until the end of 2027. The goal is to learn more about real-world…

This study looks at how doctors in Russia treat advanced lung cancer (NSCLC) in everyday practice. Researchers will follow about 1500 adults to see which treatments are used and how genetic testing guides decisions. The goal is to understand real-world care, not to test a new dru…

This study observes 137 adults with chronic lymphocytic leukemia (CLL) in Germany who are already prescribed acalabrutinib. Researchers will track how many patients continue taking the drug after 1 and 2 years in routine clinical practice. No experimental treatment is given; the …

This early-stage study looks at how the experimental drug saruparib affects other medicines in people with advanced solid tumors that have not responded to standard treatments. About 41 participants will take saruparib along with common drugs to see if it changes their levels in …